New Delhi: Drug major Ranbaxy has succesfully completed the phase II clinical trials for the first malaria drugs being developed in India since many decades and expects to start marketing it in next 3-5 years.
“The proof-of-phasing for phase II of the trials have been successfully undertaken and the drug will now undergo phase III of trials before being introduced in the market,” Ranbaxy Laboratories Senior Vice President for New Drug Discovery Research Pradip Bhatnagar told PTI.
The company has not decided upon any trade name for the drug research on which it started clinical trials in 2003-04, he said on the sidelines of the Public Private Partnership summit for Lifesciences Sector here.
The anti-malarial combination of arterolane and piperaquine is sought by the company to be exported to malaria affected countries of Asia, Africa and South America at an affordable cost once developed.
Earlier, Ranbaxy was working with the Geneva-based Medicines for Malaria Venture (MMV) on the drug development project as part of joint malaria drug research. MMV walked out of the joint project in November, 2007.
Ranbaxy has also reached agreements with international drug maker Merck for collaboration in developing anti-infectives useful in the anti-biotic, anti-viral and tuberculosis drugs segments.
“We are also working with Glaxo Smith Kline (GSK) in conducting clinical trials for drugs relating treatment of oncological problems like cancer, inflammation like asthma and metabolic diseases,” Bhatnagar said.
Regarding the recent takeover of Ranbaxy by Japan-based Daichi Group, Bhatnagar said the change of guards will have no effect on the company’s focus.
“The agreement guarantees an independent subsidiary status for Ranbaxy Laboratories and we are continuing to work on our four main focus areas, including anti-infectives, oncology, inflammation and metabolic diseases research,” he added.